• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine.传统细胞遗传学对接受维奈克拉和地西他滨治疗的急性髓系白血病的预后影响
Leuk Lymphoma. 2021 Dec;62(14):3501-3505. doi: 10.1080/10428194.2021.1973675. Epub 2021 Sep 3.
2
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.在未经治疗的老年急性髓系白血病患者中，venetoclax 联合地西他滨或阿扎胞苷的安全性和初步疗效：一项非随机、开放标签、1b 期研究。
Lancet Oncol. 2018 Feb;19(2):216-228. doi: 10.1016/S1470-2045(18)30010-X. Epub 2018 Jan 12.
3
Report of four acute myeloid leukemia patients with sustained complete remission with less frequent administration of decitabine and venetoclax.四名急性髓系白血病患者使用地西他滨和维奈克拉给药频率较低却持续完全缓解的报告。
Leuk Lymphoma. 2023 Apr;64(4):897-899. doi: 10.1080/10428194.2023.2179361. Epub 2023 Feb 27.
4
Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML.维奈克拉联合地西他滨作为新诊断的ELN不良风险急性髓系白血病年轻成人患者的一线治疗方案。
Blood. 2023 Oct 12;142(15):1323-1327. doi: 10.1182/blood.2023020102.
5
Venetoclax with decitabine or azacitidine for AML.维奈托克联合地西他滨或阿扎胞苷治疗急性髓系白血病
Lancet Oncol. 2018 Dec;19(12):e672. doi: 10.1016/S1470-2045(18)30824-6. Epub 2018 Nov 1.
6
Association between plasma venetoclax trough levels and serum C-reactive protein levels in patients with acute myeloid leukemia treated with venetoclax plus azacitidine.维奈克拉联合阿扎胞苷治疗的急性髓系白血病患者血浆维奈克拉谷浓度与血清C反应蛋白水平之间的关联
Leuk Lymphoma. 2024 Jan;65(1):128-131. doi: 10.1080/10428194.2023.2264427. Epub 2024 Jan 10.
7
Clinical status of induction therapy incorporating a hypomethylating agent for newly diagnosed adult acute myeloid leukemia compared to the standard 7+3 regimen.新诊断成人急性髓系白血病诱导治疗中联合低甲基化药物与标准 7+3 方案的临床状态比较。
Expert Rev Hematol. 2023 Jul-Dec;16(10):761-771. doi: 10.1080/17474086.2023.2256472. Epub 2023 Sep 8.
8
An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia.评价维奈托克联合阿扎胞苷、地西他滨或低剂量阿糖胞苷治疗急性髓系白血病的疗效。
Expert Rev Hematol. 2021 May;14(5):407-417. doi: 10.1080/17474086.2021.1938533. Epub 2021 Jun 15.
9
Very long-term efficacy of venetoclax combined with hypomethylating agents in two AML elderly: is it the time for treatment discontinuation strategies?维奈克拉联合去甲基化药物治疗两名老年急性髓系白血病患者的长期疗效：是否到了采用治疗中断策略的时候？
Ann Hematol. 2024 May;103(5):1787-1788. doi: 10.1007/s00277-024-05700-4. Epub 2024 Mar 9.
10
Abbreviated venetoclax with decitabine or azacitidine in acute myeloid leukemia.维奈克拉联合地西他滨或阿扎胞苷简化方案治疗急性髓系白血病
Leuk Res. 2023 Nov;134:107370. doi: 10.1016/j.leukres.2023.107370. Epub 2023 Aug 16.

引用本文的文献

1
Prognostic Impact of the AML60+ Score for Elderly Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Retrospective Multicentric Analysis.AML60+评分对接受去甲基化药物治疗的老年急性髓系白血病患者的预后影响：一项回顾性多中心分析
Cancers (Basel). 2025 Aug 14;17(16):2658. doi: 10.3390/cancers17162658.
2
Development of a clinical prediction model for sensitivity to combination therapy of Bcl-2 inhibitors and hypomethylating agents in elderly/unfit patients with acute myeloid leukemia.老年/不适合进行强化疗的急性髓系白血病患者对Bcl-2抑制剂与低甲基化药物联合治疗敏感性的临床预测模型的开发。
Discov Oncol. 2025 May 20;16(1):831. doi: 10.1007/s12672-025-02612-1.
3
Hypomethylating agent-based therapies in older adults with acute myeloid leukemia - A joint review by the Young International Society of Geriatric Oncology and European Society for Blood and Marrow Transplantation Trainee Committee.基于低甲基化剂的治疗在老年急性髓系白血病中的应用 - 老年肿瘤学的青年国际学会和欧洲血液和骨髓移植协会学员委员会的联合综述。
J Geriatr Oncol. 2023 Apr;14(3):101406. doi: 10.1016/j.jgo.2022.11.005. Epub 2022 Nov 23.

本文引用的文献

1
Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis.地西他滨联合维奈托克与强化化疗治疗复发或难治性急性髓系白血病的 10 天疗程：一项倾向评分匹配分析。
Cancer. 2021 Nov 15;127(22):4213-4220. doi: 10.1002/cncr.33814. Epub 2021 Aug 3.
2
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality.维奈托克联合地西他滨与强化化疗治疗急性髓系白血病的疗效比较：基于治疗相关死亡率风险的倾向评分匹配分析。
Am J Hematol. 2021 Mar 1;96(3):282-291. doi: 10.1002/ajh.26061. Epub 2020 Dec 24.
3
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.10天阿扎胞苷联合维奈克拉用于新诊断的不适合强化化疗以及复发或难治性急性髓系白血病的治疗：一项单中心2期试验
Lancet Haematol. 2020 Oct;7(10):e724-e736. doi: 10.1016/S2352-3026(20)30210-6. Epub 2020 Sep 5.
4
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.阿扎胞苷和维奈托克治疗未经治急性髓系白血病。
N Engl J Med. 2020 Aug 13;383(7):617-629. doi: 10.1056/NEJMoa2012971.
5
Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care.细胞遗传学和基因突变影响接受阿扎胞苷或常规治疗的老年急性髓系白血病患者的生存。
Leukemia. 2018 Dec;32(12):2546-2557. doi: 10.1038/s41375-018-0257-z. Epub 2018 Oct 1.
6
Acute myeloid leukaemia.急性髓系白血病。
Lancet. 2018 Aug 18;392(10147):593-606. doi: 10.1016/S0140-6736(18)31041-9. Epub 2018 Aug 2.
7
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.成人急性髓系白血病的诊断与管理：2017年国际专家小组的欧洲白血病网络（ELN）建议
Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28.
8
Azacitidine for the treatment of relapsed and refractory AML in older patients.阿扎胞苷治疗老年复发/难治性 AML。
Leuk Res. 2015 Feb;39(2):124-30. doi: 10.1016/j.leukres.2014.11.009. Epub 2014 Nov 24.
9
Survival for older patients with acute myeloid leukemia: a population-based study.老年急性髓系白血病患者的生存：一项基于人群的研究。
Haematologica. 2012 Dec;97(12):1916-24. doi: 10.3324/haematol.2012.066100. Epub 2012 Jul 6.
10
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.急性髓系白血病治疗试验的诊断、反应标准标准化、治疗结果及报告标准国际工作组修订建议
J Clin Oncol. 2003 Dec 15;21(24):4642-9. doi: 10.1200/JCO.2003.04.036.

Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine.

作者信息

Venugopal Sangeetha, Maiti Abhishek, DiNardo Courtney D, Qiao Wei, Ning Jing, Loghavi Sanam, Daver Naval G, Kadia Tapan M, Rausch Caitlin R, Alvarado Yesid, Ohanian Maro, Sasaki Koji, Short Nicholas J, Takahashi Koichi, Yilmaz Musa, Ravandi Farhad, Kantarjian Hagop M, Konopleva Marina Y

机构信息

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Leuk Lymphoma. 2021 Dec;62(14):3501-3505. doi: 10.1080/10428194.2021.1973675. Epub 2021 Sep 3.

DOI:10.1080/10428194.2021.1973675
PMID:34474640
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10423012/
Abstract
摘要